Evidence map›Paper›PMID 33887110›Full record

Observational studyTherapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy2021

Combination therapy with plasma exchange and glucocorticoid may be effective for severe COVID-19 infection: A retrospective observational study.

Yasushi Matsushita, Makio Kusaoi, Makoto Hiki, Goh Murayama, Yoshiyuki Abe, Kazuhisa Nozawa, Kazuhisa Takahashi, Ken Yamaji, Naoto Tamura, Toshio Naito

Open access · bronzeAbstract readCase ReportsObservational Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 3 pooled it
0.5field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 3 syntheses or guidelines pooled it, 8 citations in OpenAlex.

  1. Pooled it
  2. Use of therapeutic plasma exchange in COVID-19: A systematic review of current evidence.Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy · 2022
    Pooled it
  3. Pooled it
  4. Review
  5. Role of therapeutic plasma exchange in the management of COVID-19-induced cytokine storm syndrome.Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis · 2022
    Review
  6. Combination therapy with plasma exchange and glucocorticoid may be effective for severe COVID-19 infection: A retrospective observational study.Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy · 2021
    Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Yasushi MatsushitaDepartment of Internal Medicine and Rheumatology, Faculty of Medicine, Juntendo University, Tokyo, Japan.
Makio KusaoiDepartment of Internal Medicine and Rheumatology, Faculty of Medicine, Juntendo University, Tokyo, Japan.
Makoto HikiDepartment of Emergency Medicine, Faculty of Medicine, Juntendo University, Tokyo, Japan.
Goh MurayamaDepartment of Internal Medicine and Rheumatology, Faculty of Medicine, Juntendo University, Tokyo, Japan.
Yoshiyuki AbeDepartment of Internal Medicine and Rheumatology, Faculty of Medicine, Juntendo University, Tokyo, Japan.
Kazuhisa NozawaDepartment of Internal Medicine and Rheumatology, Faculty of Medicine, Juntendo University, Tokyo, Japan.
Kazuhisa TakahashiDepartment of Respiratory Medicine, Faculty of Medicine, Juntendo University, Tokyo, Japan.
Ken YamajiDepartment of Internal Medicine and Rheumatology, Faculty of Medicine, Juntendo University, Tokyo, Japan.
Naoto TamuraDepartment of Internal Medicine and Rheumatology, Faculty of Medicine, Juntendo University, Tokyo, Japan.
Toshio NaitoDepartment of General Medicine, Faculty of Medicine, Juntendo University, Tokyo, Japan.
Juntendo University · JP

Funding

Japanese rock band GLAY
6 · The paper itself

Abstract

We retrospectively analyzed the characteristics and outcomes of five patients with COVID-19 who were received glucocorticoid (with or without pulse therapy) and therapeutic plasma exchange. The efficacy of the treatment was determined by whether the patient was able to be transferred from the COVID-19 exclusive ICU to the general ward. In comparing patients who received prednisolone pulse therapy (three cases) with those who did not (two cases), 2/3 (66%) and 0/2 (0%) patients could be discharged from the COVID-19 dedicated ICU, respectively. Among five patients who was performed plasma exchange, two elderly male patients who underwent plasma exchange as early as within 8 days of disease exacerbation survived and were able to be transferred to the general ward. This observational study indicates that plasma exchange in conjunction with methylprednisolone pulse therapy at the appropriate time may be an effective treatment for elderly patients with severe COVID-19.

Indexed as

SARS-CoV-2AgedAged, 80 and overCombined Modality TherapyCOVID-19Fatal OutcomeFemaleGlucocorticoidsHumansMaleMiddle AgedPlasma ExchangeRetrospective StudiesTreatment OutcomeGlucocorticoidsCOVID-19glucocorticoidmethylprednisoloneplasma exchangeSARS-CoV-2

Identifiers

PMID33887110
PMCPMC8250198
OpenAlexW3153098413

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.